News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting



5/16/2013 8:47:01 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Bristol-Myers Squibb Company (NYSE: BMY) today announced that new data on its approved and investigational immuno-oncology compounds, Yervoy and the investigational PD-1 receptor blocking antibody nivolumab, will be featured in six oral presentations at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 - June 4.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES